John-john B. Schnog

Willemstad, Curaçao

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer.

Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer.

Journal: The New England journal of medicine

Published: March 26, 2026

A critical view of the BJH publication on the lack of benefit of second-line daratumumab in patients with functional high-risk multiple myeloma.

A critical view of the BJH publication on the lack of benefit of second-line daratumumab in patients with functional high-risk multiple myeloma.

Journal: British journal of haematology

Published: March 02, 2026

Uncertain magnitude of benefit of early second-generation androgen receptor antagonist treatment in advanced prostate cancer.

Uncertain magnitude of benefit of early second-generation androgen receptor antagonist treatment in advanced prostate cancer.

Journal: Oncology reviews

Published: November 20, 2025

Moving forward from spleen response as an endpoint in randomized controlled trials in myelofibrosis.

Moving forward from spleen response as an endpoint in randomized controlled trials in myelofibrosis.

Journal: Haematologica

Published: July 15, 2025

Clinical Benefit of Early Daratumumab Use in Multiple Myeloma is Undefined.

Clinical Benefit of Early Daratumumab Use in Multiple Myeloma is Undefined.

Journal: American journal of hematology

Published: April 07, 2025

Increasing the focus on critical appraisal of trials and financial conflict of interest in medical training programs: a perspective from oncology.

Increasing the focus on critical appraisal of trials and financial conflict of interest in medical training programs: a perspective from oncology.

Journal: Frontiers in medicine

Published: February 24, 2025

The Keynote-177 Randomized Controlled Trial of First-line PD-1 Blockade for Microsatellite-High or Mismatch Repair-Deficient Advanced Colorectal Cancer: Potential Consequences of the Cross-Over Trial Design and Related Issues.

The Keynote-177 Randomized Controlled Trial of First-line PD-1 Blockade for Microsatellite-High or Mismatch Repair-Deficient Advanced Colorectal Cancer: Potential Consequences of the Cross-Over Trial Design and Related Issues.

Journal: Cancer medicine

Published: February 13, 2025

Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III-IVa cervical cancer: is the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial practice changing?

Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III-IVa cervical cancer: is the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial practice changing?

Journal: Cancer

Published: November 22, 2024

Characteristics of professional society oncological drug evaluation in the Netherlands from 2016 to 2020: A retrospective analysis.

Characteristics of professional society oncological drug evaluation in the Netherlands from 2016 to 2020: A retrospective analysis.

Journal: Journal of cancer policy

Published: November 12, 2024

Fedratinib for patients with myelofibrosis.

Fedratinib for patients with myelofibrosis.

Journal: The Lancet. Haematology

Published: October 26, 2024

Design issues with lutetium-177 PSMA-617 registration studies that bias the outcome of the experimental arm reflect an increasing misalignment of contemporary oncology trials with true patient benefit.

Design issues with lutetium-177 PSMA-617 registration studies that bias the outcome of the experimental arm reflect an increasing misalignment of contemporary oncology trials with true patient benefit.

Journal: BJC reports

Published: February 29, 2024

Pharmaceutical Industry Payments to Medical Oncologists in the Netherlands: Trends and Patterns Provided by an Open-Access Transparency Data Set.

Pharmaceutical Industry Payments to Medical Oncologists in the Netherlands: Trends and Patterns Provided by an Open-Access Transparency Data Set.

Journal: JCO oncology practice

Published: February 14, 2024

Showing 1-12 of 24

Last Updated: 09/26/2026